| Home > Publications database > Regional nodal irradiation in breast cancer patients: A treatment planning study of the breast cancer working group of the German society of radiation oncology. > print |
| 001 | 305582 | ||
| 005 | 20251101115631.0 | ||
| 024 | 7 | _ | |a 10.1016/j.meddos.2025.09.006 |2 doi |
| 024 | 7 | _ | |a pmid:41168045 |2 pmid |
| 024 | 7 | _ | |a 0958-3947 |2 ISSN |
| 024 | 7 | _ | |a 1873-4022 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02241 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Duma, Marciana Nona |b 0 |
| 245 | _ | _ | |a Regional nodal irradiation in breast cancer patients: A treatment planning study of the breast cancer working group of the German society of radiation oncology. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1761918062_171917 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub |
| 520 | _ | _ | |a The aim of the study was to analyze the interinstitutional differences in the planning process/approach of regional nodal irradiation (RNI) in breast cancer patients in expert centres. Based on a predefined risk constellation, the left breast and the axillary, periclavicular and internal mammarian lymph node areas had to be irradiated. The study focused on left-sided RNI. One CT dataset (free breathing) each of a regular (R) adipose (A) and a slender patient (S) were centrally selected and all target volumes (CTV: level II, III, IV + internal mammary artery chain region-IMC, left breast, PTV and OARs) were contoured according to the ESTRO recommendations. A total dose of 50.4/1.8 Gy was set as the dosage with free choice of technique/inclinic constraints. Dose files were analyzed centrally as DICOM files (CTV: D95%, D50%, D1% and V95%; OAR: D1%, Dmean, V20Gy, V30Gy, V40Gy and the absolute V95% of normal tissue outside the PTV). A total of 18 data sets were analyzed. Differences of almost 10 Gy in TV coverage were significant (p < 0.05). This was evident between patients e.g., for CTV_IMC D95%/D50% S:47.1Gy ± 1.9/50.1Gy ± 0.6; R:39.4Gy ± 8.4/47.6Gy ± 4; A:38.3Gy ± 10.4/47.9Gy ± 4.4) and PTV_IMA D95%/D50% (S:37.6Gy ± 3.9/49.7Gy ± 0.8; R:27.9Gy ± 7.8/46.9Gy ± 3.3; A:25.6Gy ± 9.7/47.5Gy ± 2.8). Patient-related dose differences were also significant for OAR`s: Dmean heart (S:4.6Gy ± 1.1; N:6.1Gy ± 1.2; A:7.9Gy ± 2.1), humeral head (S:8.3Gy ± 2.7; N:3.8Gy ± 0.7; A:6.4Gy ± 1.7), and thyroid (S:17.7Gy ± 2.7; N:14.3Gy ± 1.6; A:27.9Gy ± 4.5). Patient anatomical factors and institutional planning differences create significant dosimetric variations in breast cancer radiation therapy, emphasizing the need for personalized planning approaches that incorporate patient-specific constraints and age-dependent risk considerations. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Breast cancer |2 Other |
| 650 | _ | 7 | |a Lymphatics |2 Other |
| 650 | _ | 7 | |a RNI |2 Other |
| 700 | 1 | _ | |a Borm, Kai |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Hehr, Thomas |b 2 |
| 700 | 1 | _ | |a Piroth, Marc D |b 3 |
| 700 | 1 | _ | |a Gerd, Fastner |b 4 |
| 700 | 1 | _ | |a Baumann, René |b 5 |
| 700 | 1 | _ | |a Combs, Stephanie E |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Corradini, Stefanie |b 7 |
| 700 | 1 | _ | |a Dunst, Jürgen |b 8 |
| 700 | 1 | _ | |a Krug, David |b 9 |
| 700 | 1 | _ | |a Hörner-Rieber, Juliane |b 10 |
| 700 | 1 | _ | |a Matuschek, Christiane |b 11 |
| 700 | 1 | _ | |a Schmeel, Leonard Christopher |b 12 |
| 700 | 1 | _ | |a Fietkau, Rainer |b 13 |
| 700 | 1 | _ | |a Strnad, Vratislav |b 14 |
| 700 | 1 | _ | |a Budach, Wilfried |b 15 |
| 773 | _ | _ | |a 10.1016/j.meddos.2025.09.006 |g p. S0958394725000561 |0 PERI:(DE-600)2000560-X |p nn |t Medical dosimetry |v nn |y 2025 |x 0958-3947 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:305582 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MED DOSIM : 2022 |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-06 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-06 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-06 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-06 |
| 920 | 1 | _ | |0 I:(DE-He78)MU01-20160331 |k MU01 |l DKTK Koordinierungsstelle München |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)MU01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|